Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerChris Parker, Oliver Sartor, Aleš Chodacki et al.|New England Journal of Medicine|2013Cited by 3.3k
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Christopher Parker, Robert L. Coleman et al.|The Lancet Oncology|2014Cited by 491
A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013).Juanita Crook, Laurence Klotz, Chris J. O’Callaghan et al.|Journal of Clinical Oncology|2011Cited by 51